Display options
Cite
Meletta R, Müller Herde A, Dennler P, et al. Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI Res. 2016;6(1):1doi: 10.1186/s13550-015-0157-4.
Meletta, R., Müller Herde, A., Dennler, P., Fischer, E., Schibli, R., & Krämer, S. D. (2016). Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI research, 6(1), 1. https://doi.org/10.1186/s13550-015-0157-4
Meletta, Romana, et al. "Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis." EJNMMI research vol. 6,1 (2016): 1. doi: https://doi.org/10.1186/s13550-015-0157-4
Meletta R, Müller Herde A, Dennler P, Fischer E, Schibli R, Krämer SD. Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI Res. 2016 Dec;6(1):1. doi: 10.1186/s13550-015-0157-4. Epub 2016 Jan 04. PMID: 26728358; PMCID: PMC4700042.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2016 Dec;6(1):1. doi: 10.1186/s13550-015-0157-4. Epub 2016 Jan 04.

Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis.

EJNMMI research

Romana Meletta, Adrienne Müller Herde, Patrick Dennler, Eliane Fischer, Roger Schibli, Stefanie D Krämer

Affiliations

  1. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 3/4, CH-8093, Zurich, Switzerland.
  2. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, OIPA10A, 5232, Villigen-PSI, Switzerland.
  3. Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 3/4, CH-8093, Zurich, Switzerland. [email protected].

PMID: 26728358 PMCID: PMC4700042 DOI: 10.1186/s13550-015-0157-4

Abstract

BACKGROUND: The inflammatory nature of atherosclerosis provides a broad range of potential molecular targets for atherosclerosis imaging. Growing interest is focused on targets related to plaque vulnerability such as the co-stimulatory molecules CD80 and CD86. We investigated in this preclinical proof-of-concept study the applicability of the CD80/CD86-binding fusion protein belatacept as a probe for atherosclerosis imaging.

METHODS: Belatacept was labeled with indium-111, and the binding affinity was determined with CD80/CD86-positive Raji cells. In vivo distribution was investigated in Raji xenograft-bearing mice in single-photon emission computed tomography (SPECT)/CT scans, biodistribution, and ex vivo autoradiography studies. Ex vivo SPECT/CT experiments were performed with aortas and carotids of ApoE KO mice. Accumulation in human carotid atherosclerotic plaques was investigated by in vitro autoradiography.

RESULTS: (111)In-DOTA-belatacept was obtained in >70 % yield, >99 % radiochemical purity, and ~40 GBq/μmol specific activity. The labeled belatacept bound with high affinity to Raji cells. In vivo, (111)In-DOTA-belatacept accumulated specifically in Raji xenografts, lymph nodes, and salivary glands. Ex vivo SPECT experiments revealed displaceable accumulation in atherosclerotic plaques of ApoE KO mice fed an atherosclerosis-promoting diet. In human plaques, binding correlated with the infiltration by immune cells and the presence of a large lipid and necrotic core.

CONCLUSIONS: (111)In-DOTA-belatacept accumulates in CD80/CD86-positive tissues in vivo and in vitro rendering it a research tool for the assessment of inflammatory activity in atherosclerosis and possibly other diseases. The tracer is suitable for preclinical imaging of co-stimulatory molecules of both human and murine origin. Radiolabeled belatacept could serve as a benchmark for future CD80/CD86-specific imaging agents.

Keywords: Atherosclerosis; Belatacept; CD80; CD86; Co-stimulatory molecules; Imaging; Inflammation

References

  1. Trends Mol Med. 2008 Dec;14(12):550-9 - PubMed
  2. Genome Biol. 2005;6(6):223 - PubMed
  3. EJNMMI Phys. 2015 Dec;2(1):31 - PubMed
  4. Clin Drug Investig. 2014 Feb;34(2):117-26 - PubMed
  5. Cardiovasc Res. 1998 Mar;37(3):799-810 - PubMed
  6. Circulation. 2004 Apr 27;109(16):2009-15 - PubMed
  7. Int Immunol. 1998 Apr;10(4):499-506 - PubMed
  8. Int J Cardiol. 2014 Jul 1;174(3):503-15 - PubMed
  9. PLoS Comput Biol. 2015 Dec 9;11(12):e1004652 - PubMed
  10. Am J Transplant. 2005 Mar;5(3):443-53 - PubMed
  11. PLoS One. 2011;6(6):e20594 - PubMed
  12. Semin Immunopathol. 2014 Jan;36(1):93-102 - PubMed
  13. Nat Protoc. 2006;1(1):314-7 - PubMed
  14. Atherosclerosis. 2004 Sep;176(1):101-10 - PubMed
  15. Nucl Med Biol. 2006 Oct;33(7):883-9 - PubMed
  16. Nat Immunol. 2011 Mar;12(3):204-12 - PubMed
  17. Basic Res Cardiol. 2007 Mar;102(2):123-32 - PubMed
  18. Int J Cardiol. 2013 Oct 3;168(3):1965-74 - PubMed
  19. J Pharm Sci. 1995 Dec;84(12):1488-9 - PubMed
  20. MAbs. 2013 May-Jun;5(3):384-96 - PubMed
  21. Eur J Immunol. 2011 Sep;41(9):2515-8 - PubMed
  22. Atherosclerosis. 2013 Sep;230(1):92-9 - PubMed
  23. Acta Histochem Cytochem. 2011 Aug 27;44(4):165-73 - PubMed
  24. BMC Immunol. 2005 Feb 08;6:4 - PubMed
  25. J Vis Exp. 2012 Jan 13;(59):null - PubMed
  26. Immunol Rev. 2005 Apr;204:128-43 - PubMed
  27. Blood. 2003 Jan 1;101(1):202-9 - PubMed
  28. Cell. 2011 Apr 29;145(3):341-55 - PubMed
  29. Circulation. 2006 Jun 13;113(23):2744-53 - PubMed

Publication Types